LIFASTUZUMAB
UNII S072MTS0FN

Substance Identification & Data

This profile provides standardized clinical and technical data for Lifastuzumab, uniquely identified by the FDA Unique Ingredient Identifier (UNII) S072MTS0FN.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 1615697-16-9 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

S072MTS0FN

CAS Registry Number

1615697-16-9

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

LIFASTUZUMAB

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C143002

National Cancer Institute reference terminology for clinical and research data.

USAN ID

CD-30

Identifier assigned by the United States Adopted Names Council.

Substance Type

protein

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Lifastuzumab. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

LIFASTUZUMAB

Common Names & Synonyms

LIFASTUZUMAB [USAN]

Systematic Nomenclature

IMMUNOGLOBULIN G1, ANTI-(HUMAN PHOSPHATE-SODIUM COTRANSPORTER NAPI3B) (HUMAN-MUS MUSCULUS MONOCLONAL MNIB2126A HEAVY CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL MNIB2126A LIGHT CHAIN, DIMER

SYS